← Leaderboards
Yves Boucher
Massachusetts General Hospital
$4,998,847
Attributed
$5,575,942
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $683.1K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,575,942 · 4
By mechanism
R01$2,790,202 · 1
P01$1,235,101 · 1
U01$1,154,190 · 1
R21$396,449 · 1
Top collaborators
- Rakesh K. Jain2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Rakesh K. Jain$48,476,214
- Mikael Pittet$14,206,093
- Dai Fukumura$13,639,390
- Jan Patrick Oscar Schuemann$8,838,029
- John M Kyriakis$5,345,121
Others in their field
Top investigators on “Cytotoxic Agent”
- David Heimbrook · Leidos Biomedical Research, Inc.$61,051,089
- Philip J Disaia · University Of California Irvine$58,513,103
- Brenda J. Weigel · University Of Minnesota$36,792,183
- Walter John Curran · Thomas Jefferson University$26,641,549
- Douglas F Nixon · J. David Gladstone Institutes$26,316,237
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$20,277,168
Research focus
Cytotoxic AgentBlood VesselsPerfusionTumorAffectCytotoxicCellsInterstitialTumor GrowthBaseLaser Scanning MicroscopyCaliberDensityNeoplasms In Vascular TissueTreatment EfficacyNeoplasm MetastasisIn VivoLosartanClinical TrialsIntravital MicroscopySignal TransductionHypoxiaDesmoplasticFibroblasts
Grant awards (19)
Reprogramming PDAC tumor microenvironment to improve immunotherapy$577,095
U01 · FY2021 · CA
Reprogramming PDAC tumor microenvironment to improve immunotherapy$577,095
U01 · FY2020 · CA
Targeting Stroma to Improve Therapy of Pancreatic Adenocarcinoma$251,616
P01 · FY2016 · CA · contact PI
Targeting Stroma to Improve Therapy of Pancreatic Adenocarcinoma$251,616
P01 · FY2015 · CA · contact PI
Targeting Stroma to Improve Therapy of Pancreatic Adenocarcinoma$243,126
P01 · FY2014 · CA · contact PI
Breakdown of Desmoplasia in Pancreatic Cancer to Enhance Drug Effectiveness$211,859
R21 · FY2014 · CA · contact PI
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an$262,036
R01 · FY2013 · CA · contact PI
Targeting Stroma to Improve Therapy of Pancreatic Adenocarcinoma$236,524
P01 · FY2013 · CA · contact PI
Breakdown of Desmoplasia in Pancreatic Cancer to Enhance Drug Effectiveness$184,590
R21 · FY2013 · CA · contact PI
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an$278,762
R01 · FY2012 · CA · contact PI
Targeting Stroma to Improve Therapy of Pancreatic Adenocarcinoma$252,219
P01 · FY2012 · CA · contact PI
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an$278,762
R01 · FY2011 · CA · contact PI
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an$287,384
R01 · FY2010 · CA · contact PI
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an$286,978
R01 · FY2009 · CA · contact PI
Viral Vectors in Tumors: Effects of Taxol and Radiation$268,835
R01 · FY2007 · CA · contact PI
Viral Vectors in Tumors: Effects of Taxol and Radiation$276,864
R01 · FY2006 · CA · contact PI
Viral Vectors in Tumors: Effects of Taxol and Radiation$283,527
R01 · FY2005 · CA
Viral Vectors in Tumors: Effects of Taxol and Radiation$283,527
R01 · FY2004 · CA
Viral Vectors in Tumors: Effects of Taxol and Radiation$283,527
R01 · FY2003 · CA